Zevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $28.00 at Citizens Jmp

Zevra Therapeutics (NASDAQ:ZVRA) had its price target hoisted by research analysts at Citizens Jmp from $25.00 to $28.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has a “market outperform” rating on the stock. Citizens Jmp’s price objective suggests a potential upside of 165.91% from the stock’s previous close.

Several other research firms also recently weighed in on ZVRA. BTIG Research lowered their price target on shares of Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating for the company in a research note on Monday, July 27th. Wall Street Zen raised Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Canaccord Genuity Group decreased their price objective on Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating on the stock in a report on Monday, July 27th. Maxim Group boosted their target price on Zevra Therapeutics from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th. Finally, UBS Group restated a “buy” rating on shares of Zevra Therapeutics in a report on Wednesday, June 24th. Nine analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $27.29.

Zevra Therapeutics Price Performance

Shares of ZVRA opened at $10.53 on Thursday. The firm has a market cap of $622.48 million, a P/E ratio of 5.29 and a beta of 0.91. The stock has a 50 day simple moving average of $12.31 and a two-hundred day simple moving average of $10.55. Zevra Therapeutics has a 1 year low of $7.16 and a 1 year high of $15.03.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.11 by $0.14. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. The firm had revenue of $39.66 million for the quarter, compared to the consensus estimate of $33.88 million. On average, equities analysts anticipate that Zevra Therapeutics will post 0.56 earnings per share for the current year.

Institutional Trading of Zevra Therapeutics

A number of institutional investors have recently modified their holdings of the company. AIGH Capital Management LLC purchased a new stake in Zevra Therapeutics in the 1st quarter worth approximately $11,184,000. Marshall Wace LLP purchased a new position in shares of Zevra Therapeutics during the third quarter valued at approximately $8,676,000. Rubric Capital Management LP raised its holdings in shares of Zevra Therapeutics by 60.8% during the second quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock valued at $17,253,000 after acquiring an additional 740,584 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in Zevra Therapeutics by 15.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock worth $36,720,000 after acquiring an additional 550,000 shares during the period. Finally, Nantahala Capital Management LLC lifted its stake in Zevra Therapeutics by 34.0% in the third quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company’s stock worth $18,753,000 after acquiring an additional 500,000 shares during the period. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.